Eli Lilly has launched its diabetes and weight-loss drug, Mounjaro, in India, making it the first to introduce the medication in the country, ahead of rival Novo Nordisk. Mounjaro, a once-weekly injection, has been approved by India’s drug regulator and is priced at 4,375 rupees ($50.67) for a 5 mg vial and 3,500 rupees ($40.54) for a 2.5 mg vial. The highest dose available is 15 mg. Patients may spend about $200 a month for a weekly 5 mg dose, which is substantially lower than its U.S. price of $1,086.37 per month.

Mounjaro, also known as tirzepatide, is used for both diabetes management and weight loss in various regions. In the U.S. it is sold under the name Zepbound for obesity, while in the UK and Europe, it is marketed for both conditions under the Mounjaro brand. Despite this, Lilly noted that prices differ significantly across regions due to various healthcare systems, economies, and reimbursement policies.

For more details please visit our website - https://www.medhealthinsight.com/eli-lilly-debuts-mounjaro-in-india-outpaces-novo-nordisk/